3M reaches $6B hearing damage settlement

Today’s Big News

Aug 29, 2023

Drugs from J&J, Merck, Novartis, BMS and more set for first round of Medicare price negotiations: CMS 


LIB's cholesterol-busting drug aces 2nd phase 3 trial, keeping Amgen blockbuster in its sights 


3M reaches $6B settlement over claims that defective military earplugs led to hearing damage 


With Novo’s Wegovy on the rise, AstraZeneca’s Ruud Dobber thinks Farxiga can hold its own 


Activist investors once again take AIM at biotech working on treatment for long COVID symptoms 


Withings’ ECG-equipped smart scale earns FDA clearance for afib detection 


Bristol Myers Squibb's Reblozyl, chasing $4B sales target, wins key FDA label expansion 


Introducing Fierce Biotech's 2023 Fierce 15 

 

Featured

Drugs from J&J, Merck, Novartis, BMS and more set for first round of Medicare price negotiations: CMS

The drugs that made the cut for the first price negotiations are Johnson & Johnson’s Imbruvica, Stelara and Xarelto plus Bristol Myers Squibb’s Eliquis, Merck & Co.’s Januvia, Novartis’ Entresto, Eli Lilly’s Jardiance, AstraZeneca’s Farxiga, Novo Nordisk’s Fiasp and Amgen’s Enbrel.
11-14
Sep
Philadelphia, PA
 

Top Stories

LIB's cholesterol-busting drug aces 2nd phase 3 trial, keeping Amgen blockbuster in its sights

LIB Therapeutics has passed another milestone on its path to launching a challenger to cholesterol drugs sold by Amgen, Regeneron and Sanofi. In the latest phase 3 readout, the private biotech’s subcutaneous PCSK9 inhibitor cut levels of LDL cholesterol to maintain momentum going into the final two data drops.

3M reaches $6B settlement over claims that defective military earplugs led to hearing damage

After spending the better part of the last decade defending itself from claims that it knowingly sold defective earplugs to the U.S. military, resulting in thousands of reports of hearing loss among service members, 3M has reached a settlement in a far-reaching class-action lawsuit over the matter.

With Novo's Wegovy on the rise, AstraZeneca's Ruud Dobber thinks Farxiga can hold its own

GLP-1 agonists such as Novo Nordisk’s semaglutide and SGLT2 inhibitors like AstraZeneca’s Farxiga are already bumping heads in diabetes treatment. AstraZeneca’s biopharma business president, Ruud Dobber, said he’s not concerned about a potential upcoming clash between the two classes in heart failure.

Activist investors once again take AIM at biotech working on treatment for long COVID symptoms

A group of activist investors is once again taking on AIM Immunotech's leadership, suing the company for changes to its bylaws made earlier this year. The company rejected three board nominations earlier this month.

Withings’ ECG-equipped smart scale earns FDA clearance for afib detection

In recent years, electrocardiogram technology has become increasingly widely available, embedded into dedicated portable devices, smartwatches and, now, even bathroom scales.

Bristol Myers Squibb's Reblozyl, chasing $4B sales target, wins key FDA label expansion

The first-line anemia use in MDS represents a key milestone as Bristol Myers targets $4 billion in peak sales for the new medicine.

Introducing Fierce Biotech's 2023 Fierce 15

This year's Fierce 15 features companies pushing the envelope not only in the lab, in the clinic or on the conference circuit.

Apellis lays off 25%, culls preclinical programs to free up cash for Syfovre's growth

While it continues to hone in on the cause of a rare side effect linked to its geographic atrophy drug Syfovre, Apellis has decided to lay off a quarter of its workforce and cull its two preclinical assets to claw back $300 million in savings.

Ginkgo, Google Cloud ink AI tie-up with eyes on protein modeling

The company hopes to turn the type of technology that underpins programs such as ChatGPT toward synthetic biology by training models on genomic and protein data instead of internet images or the written word.
 
Fierce podcasts

Don’t miss an episode

‘The Top Line’: Cannes Lions, top paid CEOs, and a drug shortage

This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage

 

Resources

Whitepaper

Plan for success with your process liquid and buffer preparation

Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity.
Whitepaper

Key Drivers of Sales Force Strategy in Oncology

In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today.
Research

Reduce chemical lead times with just-in-time delivery

Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery.
Webinar

Novel Antibodies for the Characterization of CAR-T Cells

Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more.
 

Industry Events

 

Upcoming Fierce Events

11-14
Sep
Philadelphia, PA
13
Sep
Philadelphia, PA
19-21
Sep
Virtual Event
26-28
Sep
Philadelphia, PA
5-6
Oct
San Diego, CA

View all events